X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Central Pharma partners with Supply Chain Wizard to advance digital capabilities

Content Team by Content Team
6th March 2019
in Manufacturing, News, Packaging & Logistic
Central Pharma partners with Supply Chain Wizard to advance digital capabilities

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Global contract packaging organization (CPO) Central Pharma has collaborated with Supply Chain Wizard to optimize its digital operations.

The deal enables Central Pharma to access the latest IoT technology solutions via fully integrated digital factory suite of Supply Chain Wizard.

Central Pharma chairman Alwyn Smit said: “Partnering with Supply Chain Wizard will help drive our business toward achieving its goal of having a world class manufacturing status. Our New Facility in Ireland will be a Digital Factory, the Supply Chain Wizard team have been excellent in getting their software up and running which has added value to our daily operations at our UK production facility.”

The integrated digital factory suite is comprised of solutions for overall equipment effectiveness (OEE) tracking, scheduling and digitally logging production related information.

Supply Chain Wizard’s advanced tools can be used in primary and secondary packaging operations.

The tools will enable Central Pharma and its customers to take data-driven decisions, as well as enhance overall production efficiency and productivity across its blistering, powder and container lines.

Supply Chain Wizard founder and CEO Dr Evren Ozkaya said: “This partnership has the potential to become a digital transformation success story & a model digital factory showroom for manufacturing companies to visit & learn from Central Pharma’s experience.”

“Central Pharma is a client & partner with one of the most innovative mindsets & high aspirations to create a competitive advantage through digital transformation, and we hope this is the start of a long and successful relationship.”

Founded in 2006, Central Pharma provides contract packaging services to healthcare organizations across the globe.

The company provides a range of warehousing options, including both temperature controlled and ambient monitored storage. At present, the firm operates three storage facilities, which cover more than 5000m² and has capacity in excess of 3000 pallet locations.

Central Pharma also offers track and trace services, as well as full aggregation and data management services to the customers.

Previous Post

NovaGo Therapeutics Raises CHF 10 Million to Develop Regenerative Anti-Nogo Therapy for Stroke

Next Post

TrialAssure Announces Transparency Application that Anonymizes Patient Data in Clinical Trials

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
TrialAssure Announces Transparency Application that Anonymizes Patient Data in Clinical Trials

TrialAssure Announces Transparency Application that Anonymizes Patient Data in Clinical Trials

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In